Diabetic Retinopathy

Ocular Therapeutix announced that more than 300 patients have been randomly assigned in the SOL-1 phase 3 trial for Axpaxli, an investigational axitinib intravitreal implant for wet age-related macular degeneration.

Catch up on Healio’s news in diabetic retinopathy for Diabetes Awareness Month.

AI continues to change the landscape of retinal disease management regarding diagnosis, monitoring and treatment, and an AI software from India may elevate the field even further.

Evaluations of diabetic retinopathy severity appeared comparable with ultra-widefield and 7-field imaging, suggesting ultra-widefield imaging can be used in future longitudinal studies without bias, according to a cross-sectional study.

Although best corrected visual acuity was the only visual function test ready for immediate use in a diabetic retinal disease staging system, others showed promise or potential, according to a report published in Ophthalmology Science.

NEW YORK — In this Healio Video Perspective from OSN New York, Sanjay Nayak, MBBS, PhD, of Ocular Therapeutix discusses Axpaxli for the treatment of retinal vascular diseases.

Patients with type 2 diabetes recently diagnosed with diabetic retinopathy had a significantly reduced concentration of progranulin in their tears compared with control patients, according to prospective study results.

A novel primary care optometry-based diabetic retinopathy service served as an efficient, safe alternative to hospital services and offered advantages over virtual clinics, according to a study conducted in the U.K. and published in Eye.

CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Peter K. Kaiser, MD, of Ocular Therapeutix, discusses the company’s shift to a retina-focused program.

INDIANAPOLIS — A single in-office treatment of ABBV-RGX-314 was well-tolerated and improved severity of diabetic retinopathy, according to 1-year study results presented at Academy 2024.